Secondary malignancy after imatinib therapy: eight cases and review of the literature. - Wikidata - wikimedia - TriplyDB

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

http://www.wikidata.org/entity/Q37983587

about

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature.Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors.Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report.An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States.Chronic myeloid leukemia and risk of second malignancy in two eras of treatment.Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study

P2860

Q36123511-B730C743-39C7-4D04-812E-42F3197C026D Q38587961-AA553EC2-C06A-4FB9-A7BE-AB84C589E91D Q38753313-681A75BB-F71C-4CF3-9DD9-F46261053B48 Q39433823-C6142E40-BA68-4813-8F12-A2440BF3CB3F Q44085221-092DA044-BFC6-483C-8A0F-E2CD177A39EF Q45817260-8ECB33BF-FFB7-441E-B187-B88F345AB662 Q49873738-BA555DB1-726C-4CA4-BCD6-BFAD79C079F5 Q54527633-A7A35D68-F15E-4661-A125-7DDEEBB13B0B Q58732194-D34828B3-6BB3-4928-8635-FDEFFD2944DD

P2860

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

http://www.wikidata.org/entity/Q37983587

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@en

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@nl

type

label

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@en

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@nl

prefLabel

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@en

Secondary malignancy after imatinib therapy: eight cases and review of the literature.

@nl

P1433

Q37983587-5E09D159-5C37-4DF8-94A8-CABD27A2AAB1

P1476

Q37983587-7BE63B92-0350-43CC-831A-7E82823A5C41

P2093

Q37983587-1B5FA519-9B2B-409A-AD67-2CC418B19B2F

Q37983587-472D03B5-64CA-4F2F-85A3-73654C4B1D6C

Q37983587-53BF510A-53E9-4EDD-93A3-668A7A7191D6

Q37983587-77728BC6-1BFE-4BA5-AFCC-5DA517867E4F

P2860

Q37983587-125A717B-E61E-4A4A-A522-B3BA6E4D4F86

Q37983587-15BF6314-EBE8-4BB4-9CD5-9979A604F05F

Q37983587-61FCCF0D-B501-4CBC-87DE-0E3C6B2A257B

Q37983587-BC218905-D5CF-49D1-BBC1-FE1250E4223A

Q37983587-C59B6B1A-5BB4-4D77-9D81-8C2BDF0C9182

Q37983587-DFC28581-59A0-4378-BAD7-40604B654236

Q37983587-E2C712D7-7786-477B-978D-136171143B7B

Q37983587-EC656C84-7502-4A7E-BC9D-5B81F2AB6DB4

Q37983587-EF055907-7781-4F4E-B0EB-F6C56CA25A2F

P304

Q37983587-1DC1F805-ED3C-49C8-9235-FB03FA28CB8A

P31

Q37983587-1EEA893A-189D-42A0-A427-3F7101C8C4A4

P356

Q37983587-39A891BC-3045-459D-9FF3-C264E0C1AB6C

P433

Q37983587-9A2F3C5B-15DD-40E5-A4FD-3F77FB42A00A

P478

Q37983587-62003F78-90EC-409B-AFB4-60FA9DCCDD3D

P50

Q37983587-2EF4DB74-A658-4013-BD26-C4787DEB110E

P577

Q37983587-593D788E-6218-46C7-942B-D794932A3129

P5875

Q37983587-E750F485-2ACB-4BC7-AF2F-1AF8AC05C2EF

P698

Q37983587-A74D187C-38B2-4E8D-A6A9-292D201778B0

P356

10428194.2012.666545

P1433

Leukemia & Lymphoma

P1476

Secondary malignancy after imatinib therapy: eight cases and review of the literature

@en

P2093

Ayberk Besen

http://www.w3.org/2001/XMLSchema#string

Berna Bozkurt Duman

http://www.w3.org/2001/XMLSchema#string

Semra Paydas

http://www.w3.org/2001/XMLSchema#string

Umut Disel

http://www.w3.org/2001/XMLSchema#string

P2860

Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.

ARG tyrosine kinase activity is inhibited by STI571.

Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.

Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.

Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor.

Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib.

P304

1706-1708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.666545

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221827644

http://www.w3.org/2001/XMLSchema#string

P698

22329351

http://www.w3.org/2001/XMLSchema#string